ProSomnus Sleep Technologies CEO Liptak on Solving Sleep Apnea, Going Public – Yahoo Finance
Len Liptak, Co-founder & CEO
By IPO Edge Editorial Staff
IPO Edge: Can you give me a short description of what ProSomnus does?
ProSomnus is a pioneer of precision intraoral medical devices that represent a new option for patients suffering from a chronic disease called obstructive sleep apnea.
IPO Edge: What is Obstructive Sleep Apnea?
Obstructive Sleep Apnea is the repeated blockage of the airway at night while people are sleeping. Snoring is the biggest indicator of a disease that can be most harmful for patients, where they literally stop breathing at night. People who stop breathing at night are deprived of oxygen, which in turn can lead to a whole series of systematic problems for the person with sleep apnea.
IPO Edge: How big a problem is Sleep Apnea?
Sleep Apnea or OSA (Obstructive Sleep Apnea) is a highly prevalent disease. A billion people worldwide have it. Seventy million people in North America are believed to have OSA with 90% being undiagnosed and left untreated. The big challenge for people with OSA is remaining undiagnosed. Left untreated, OSA is associated with very severe comorbidities, from cardiovascular disease to increased incidence of stroke.
IPO Edge: What is the ProSomnus solution to Sleep Apnea?
The ProSomnus device is an easy and simple noninvasive, and non-intrusive device, that somebody can slip into their mouth and hold their jaw forward in a very comfortable way. It precisely holds the jaw in a forward position that opens the airway and allows the patient to breathe throughout the night so they are not depriving the body of oxygen—it is a therapeutic solution that allows OSA patients to get a better night’s sleep.
IPO Edge: CPAP has been in the news a lot why do you offer a better solution?
CPAP is a device. It stands for Continuous Positive Airway Pressure. As the name implies, whenever there’s a blockage or obstruction of the airway, CPAP uses just air to push it through the blockage and down the throat to ensure that the patient can get access to oxygen. CPAP has been shown to be highly efficacious at overcoming those blockages. But, we probably are all aware, that the big challenge with CPAP is a lot of people struggle to tolerate it, whether the pressure is too high or the mask does not fitting correctly. Or, maybe it’s too loud. It can often interfere with the patient’s bedtime routine and their bedtime hygiene. So, for all of those reasons, people have a hard time adapting to CPAP. That’s why we came up with ProSomnus. We wanted to have a solution that was easy and simple, noninvasive, non-intrusive, something that somebody could just slip in their mouth to hold their jaw forward in a very comfortable way, allowing them to have a conversation with their bed partner, drink a glass of water and pursue a normal bedtime routine.
IPO Edge: How does ProSomnus benefit from modern personalized/precision medicine?
Precision medicine is a concept that has revolutionized the standard of care across all fields of medicine, and is prevalent in what we do with sleep medicine. Our devices are designed to perfectly match the patient’s teeth as well as perfectly match the jaw prescription for the patient. We do this with less than 0.3 millimeters of precision, which allows us to put the jaw in the correct position to open the airway, but not over-advance the jaw so it’s uncomfortable or not under-advance the jaw so that the treatment isn’t as effective. We use milling robotics and AI-driven device design so that we can customize all of our devices. ProSomnus has built an entire digital manufacturing process around doing this. It allows us to take advantage of high-performance, medical-grade materials and produce a product that matches the prescription, treatment plan, and the anatomy for that patient with a high degree of precision. All of that has been associated in clinical studies with improved outcomes, fewer side effects, and greater patient preference.
IPO Edge: Does Medicare or Medicaid, insurance in general pick up the cost if someone has been properly diagnosed?
Yes, it a covered benefit through Medicare and the vast majority of major insurance providers.
IPO Edge: How big is your customer base?
We are focusing on a healthcare sector with high gross potential. We currently have thousands of providers who are actively prescribing our devices. But there is really no ceiling on the market. As a disruptive technology in North America, we see the market at a multi-billion dollar opportunity and on a global basis over 50 billion dollars.
IPO Edge: Why a SPAC?
ProSomnus chose to pursue the SPAC route because we had a very deliberate, multi-faced plan for how we wanted to commercialize the business and we felt that we’d achieved our goals for phase one, which were to validate our value proposition, validate our manufacturing approach, validate that our devices worked clinically, validate our business model and our commercial approach. Once we felt pretty confident that we had validated those, let’s say, phase one milestones for our company, then we knew that we wanted to scale up the business and invest in expanding our sales team, expanding internationally, investing in the technology we spoke about earlier to help expand our gross margin but scale up our manufacturing. Our combination with Lakeshore presented that opportunity, and today we are trading on the Nasdaq under the symbol OSA (Obstructive Sleep Apnea).
Contact:
IPO-Edge.com
Editor@IPO-Edge.com
Related Quotes
Top stocks moving after hours on Wednesday, December 7, 2023.
(Bloomberg) — Economists are split on whether the Bank of Canada will raise its overnight rate by 25 basis points or 50 basis points. Royal Bank of Canada rates strategist Jason Daw said the central bank may send a clear signal about the future by changing a single word. Most Read from BloombergPutin Calls Russian Nukes Deterrent Factor, Says War Risk RisingPeru’s President Accused of Coup After Move to Dissolve CongressMusk Spars With San Francisco Over Probe of Bedrooms at TwitterStock Trader
Drata, a security compliance and automation platform that helps companies adhere to frameworks such as SOC 2 and GDPR, has raised $200 million in a Series C round of funding co-led by Iconiq Growth and GGV Capital, valuing the company at $2 billion. The raise comes just a year after the San Diego-based company hit unicorn status off the back of a $100 million Series B funding round, while in the intervening months rivals in the space, including Secureframe and Laika, have each raised $50 million-plus, while Vanta secured $150 million across two tranches this year at a valuation north of $1.6 billion. The reason may be somewhat obvious, vis-à-vis data is the cornerstone of just about every modern-day business, powering everything from AI applications and CRM systems to digital medical services.
Equillium Inc (NASDAQ: EQ) announced an option and asset purchase agreement through which Ono Pharmaceutical Co Ltd gains the exclusive option to purchase Equillium's rights to itolizumab. These rights include all therapeutic indications and the rights to commercialize itolizumab in the U.S., Canada, Australia, and New Zealand. Through this partnership, Equillium has secured the resources necessary to continue advancing the Phase 3 EQUATOR study of itolizumab in the treatment of first-line acute
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like…
Wake up and smell the diesel.
Shares of Mirati Therapeutics (NASDAQ: MRTX) slumped more than 28% on Wednesday. On Monday, the company released early phase 2 data on Adagrasib to treat non-small cell lung cancer (NSCLC), along with Keytruda, which is sold by Merck (NYSE: MRK). On Wednesday, Mirati presented the data from its Krystal 7 and Krystal 1 trials with Adagrasib, at the 2022 ESMO Immuno-Oncology Annual Congress.
As we kick off Thursday trading, here's why we're eyeing renewed recession talk and Tesla and GameStop stocks. Catch us live at 9:30 a.m. ET.
Have an issue with your financial adviser or looking to hire a new one? Email picks@marketwatch.com.
The battery innovator is making progress on its lithium-metal batteries, but it still has a couple of years to go before it could start booking meaningful revenue.
Sam Bankman-Fried's ambition for celebrity endorsements might have snared the "Anti-Hero" singer, but she proved to be smarter than a lot of other famous people.
While speaking at Benzinga’s Future of Crypto event, investments in and by FTX were discussed as one of the biggest topics impacting the cryptocurrency sector. Kevin O’Leary was an investor in FTX and Anthony Scaramucci’s Skybridge Capital received an investment from FTX. Both shared their takeaways from the event of FTX and what happened with Sam Bankman-Fried. FTX Investments: Scaramucci said that many did not see warning signs with 25 of the greatest venture capitalists investing in FTX. Acco
Should you invest in a CD? The Fed's recent moves have sent interest rates—and APYs—higher.
Lisa Su has overseen what is widely considered to be one of the greatest turnaround stories in corporate history. When she became chief executive officer of Advanced Micro Devices (NASDAQ: AMD) in late 2014, the chipmaker was fighting for its survival. Today, AMD stands as a $115 billion titan in the semiconductor industry — and it's poised to become even larger and more valuable in the years ahead.
(Bloomberg) — The Federal Reserve hasn’t had much success so far in wrestling down sky-high inflation, but its monetary tightening campaign is having a major impact in deflating asset bubbles that swelled during the pandemic.Most Read from BloombergPutin Calls Russian Nukes Deterrent Factor, Says War Risk RisingPeru’s President Accused of Coup After Move to Dissolve CongressWhy Did So Many US Men Quit Working? Social Status May Hold the Key, Study SaysElon Musk’s Bankers Consider Tesla Margin L
Unfortunately, the stock has lost a lot of value since I made my initial investment. As interest rates fell, many borrowers refinanced their mortgages to lower rates. This forced Annaly to make lower-yielding investments, which impacted its income and its ability to pay dividends.
Economic uncertainty has battered the stock market this year, sparking recession fears that have driven the S&P 500 and the Nasdaq Composite into bear market territory. During that downturn, PayPal Holdings (NASDAQ: PYPL) has seen its share price nosedive 76%, marking its greatest loss of value since it became a public company (for the second time) in 2015. PayPal operates a two-sided payments network with 432 million active accounts, including 397 million consumers and 35 million merchants.
The Dow Jones Industrial Average rallied 125 points Thursday after jobless claims data. Tesla stock neared its 2022 lows.
The rollercoaster ride continues in the stock market, and equities have been falling across the board this week. The S&P 500 is down 3.5%, and the Dow has lost some 870 points. The market drop was fueled by uncertainty; recent economic data has been unexpectedly positive, and it’s clouded the forecast for the Fed’s interest rate decision next week. The central bank’s twin mandates, to rein in inflation and to moderate unemployment, frequently run counter to each other, and with inflation running
Worried about the prospect of a recession coming next year? Well, that sounds like a mild scenario, if Michael Burry’s prognosis is anything to go by. The investor whose famous bet against the US housing market was documented in “The Big Short,” thinks a ‘multi-year recession’ is potentially in the cards – and one more severe than currently expected. This statement follows previous warnings regarding the economy, such as predicting last year that the ‘mother of all crashes’ is coming, while also